Findings from one of the largest HIV/AIDS therapy studies conducted to date show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause.
Magnets may interfere with the operation of pacemakers and implantable cardioverter defibrillators, according to a study published in the December 2006 edition of Heart Rhythm.
British scientists have discovered that red wines from the two regions — Sardinia and Pyrenees — boast the highest concentrations of a chemical that underlies the drink’s well-publicised benefits for cardiovascular health. The new study, published in the journal Nature.
Taking HIV patients off medications during periods when the disease appears to be under control is a risky – and sometimes fatal – treatment strategy, according to a large international study published in the New England Journal of Medicine.
There is as much as a four- to five-fold increased relative risk for late thrombosis, or blood clot formation, in patients with drug-eluting stents compared to those with bare-metal stents, according to a Cleveland Clinic-led meta-analysis appearing in the December issue of the American Journal of Medicine. This is the first published analysis of its kind.
Researchers at Johns Hopkins have discovered what they believe is the “smoking gun” responsible for most tissue and organ damage after a period of blood oxygen loss followed by a sudden restoration of blood oxygen flow.
University of Alberta researchers have pinpointed a section in the tiny hummingbird’s brain that may be responsible for its unique ability to stay stationary mid-air and hover.
Scientists at Wake Forest University Baptist Medical Center and colleagues at four other medical centers have launched a $10 million multi-year study to identify genes that may contribute to early atherosclerosis.
Barr Pharmaceuticals, Inc. (NYSE: BRL) and its subsidiary PLIVA d.d. (LSE: PLVD; ZSE: PLVA-R-A) today announced that PLIVA has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) to manufacture and market Pravastatin Tablets 10mg, 20mg, and 40mg, the generic version of Bristol-Myers Squibb’s PRAVACHOL(R) (Pravastatin Sodium) Tablets. The Company plans to launch its product immediately. PLIVA has also received tentative approval for its Pravastatin Tablets 80mg strength and plans to launch this strength following the expiration of a competitor’s 180-day generic drug exclusivity period and subsequent final approval of PLIVA’s application.
Researchers at Harvard Medical School’s Brigham and Women’s Hospital compared the effects of a variety of immunosuppressive agents on cardiovascular events in a large sample of RA patients.